FOLR1 ADC resensitizes colorectal tumors to anti-PD-1 in mice
An approved FOLR1 antibody-drug conjugate restored anti-PD-1 activity in resistant colorectal tumors in mice, linking FOLR1, STAT1 and MHC-I with a defined molecular mechanism.
TAG E-3628 · 624 words on the filing

Summary of findings
- Only 15% of patients with colorectal cancer experience substantial benefit from treatments such as anti-PD-1.
- Mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade in mice.
- High FOLR1 expression predicted poor ICB response, enhanced cancer stemness and unfavorable patient outcomes.
- FOLR1 stabilized AARS1, enabling STAT1 lactylation at K193, TCPTP interaction and STAT1 dephosphorylation at Y701.
By Olivia Hart
Only 15% of patients with colorectal cancer experience substantial benefit from immune checkpoint blockade treatments such as anti-PD-1, according to a new study. Colorectal cancer is the third most common cancer worldwide, and resistance to checkpoint blockade remains a central development problem.
The study, published in Science Translational Medicine under the title “Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer,” identifies folate receptor α (FOLR1) as a driver of immune evasion.
Mirvetuximab soravtansine, an approved FOLR1-targeting antibody-drug conjugate, restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade in mice. The reported combination efficacy came from mouse studies, while mechanistic findings also drew on in vitro experiments.
FOLR1 emerges as a resistance node
Researchers used fluorescence-activated cell sorting-based CRISPR activation screens with a druggable genome library and identified FOLR1 as a top negative regulator of immune checkpoint blockade, or ICB, response. The researchers said: “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”
Previous work had linked FOLR1 to more aggressive disease progression and poorer prognosis across several solid-tumor types. The new data place that association in an immunotherapy-resistance pathway. In colorectal tumors, defects in MHC-1 expression already impede antitumor immunity; loss of MHC-I antigen presentation drives immune evasion and resistance to immune checkpoint blockade.
Proteomic analysis supplied a molecular bridge. FOLR1 stabilized AARS1, or alanyl-tRNA synthetase 1, which acts as a lactyltransferase. AARS1 lactylated signal transducer and activator of transcription 1, or STAT1, at lysine-193, or K193. That modification facilitated STAT1 interaction with TCPTP, or T cell protein-tyrosine phosphatase, and induced STAT1 dephosphorylation at tyrosine-701, or Y701.
In vitro, FOLR1 indirectly impaired STAT1 signaling and dampened MHC-1 activity. That pathway supported cancer-cell adaptability and prevented CD8+ T cells from engaging tumor cells. The mechanism connects FOLR1 expression with an antigen-presentation defect that can blunt anti-PD-1 therapy.
Approved ADC reverses the phenotype
The team tested mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. In the mouse experiments, the ADC restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade. The result paired FOLR1 inhibition with renewed checkpoint activity in resistant disease.
The authors wrote: “Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer].”
No clinical efficacy or dosing results accompanied the finding, and the therapeutic conclusion remains preclinical. The study did, however, connect target expression, a specific signaling mechanism, resistance in vivo and an approved molecule already available for clinical use.
The authors suggest that integrating FOLR1-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors. That proposal remains tied to the preclinical findings.
What does this change for colorectal cancer programs?
It gives developers a defined combination hypothesis: test FOLR1-directed treatment with anti-PD-1 in colorectal cancer selected for high FOLR1 expression and poor checkpoint response. High FOLR1 also marked greater cancer stemness and unfavorable patient outcomes, strengthening the case for expression-based patient selection.
For a portfolio team, the immediate asset is not another unvalidated pathway. It is a repurposing route around an approved ADC, backed by mechanistic evidence that FOLR1 sustains immune escape through AARS1-dependent STAT1 lactylation, MHC-1 suppression and CD8+ T-cell disengagement.
The next decision is whether the combination can reproduce the mouse result in patients and whether high FOLR1 provides a reliable selection marker. For now, the actionable conclusion is narrow: FOLR1 blockade merits clinical pairing with anti-PD-1, with patient efficacy as the decisive test.
via science.org (Original)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- V-7932
- K-9861
- P-9899
- C-4460
- V-1848